Filing of patent applications for the PCI technology in vaccination

Oslo, 29 August 2013 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that it has filed several patent applications within the area of vaccines. These applications will give PCI Biotech the opportunity to obtain further patent protection for the use of the PCI technology in vaccination, supplementing the already granted and pending patents within thisarea. PCI has the potential to enhance both prophylactic and therapeutic vaccines against a variety of diseases, such as cancer and infectious diseases. The term of any granted patents resulting from this application would last until August 2033.